Overview

Windlas Healthcare formulation business has its footprints in the following countries currently

  • India
  • Myanmar
  • Vietnam
  • Commonwealth of Independent States (CIS) countries

Our manufacturing facility, which is situated in Dehradun, has received approvals from USFDA, Ukraine, Kenya, Ivory Coast and Malawi. It operates an EU-cGMP approvable plant. We also have a dedicated R&D facility for formulations development.

Windlas Healthcare was established with a long-term vision to develop and deliver complex generic products to regulated markets. Besides working on our own pipeline for regulated markets, we also invite contract manufacturing projects and co-development projects for regulated markets.

Besides working on our own pipeline for regulated markets we also invite contract manufacturing projects and co-development projects for regulated markets.

We provide an array of services including site transfers, and exhibit batches for filing in USA. The plant enjoys various fiscal incentives including excise duty exemptions till FY 2019. The Plant has been approved by various multinationals including Pfizer, Sanofi, GSK and Astra Zeneca. Windlas Healthcare has developed four ANDAs First-to-File in the last two years.